financetom
Business
financetom
/
Business
/
Analog chipmaker TI tempers capital expenditure plans amid activist pressure
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Analog chipmaker TI tempers capital expenditure plans amid activist pressure
Aug 20, 2024 9:09 AM

Aug 20 (Reuters) - Texas Instruments ( TXN ) on Tuesday

pulled back on its annual capital expenditure plans while it

expands manufacturing capacity, as the analog chipmaker faces

pressure from activist investor Elliot Investment Management to

temper expenses.

The company now expects capital expenditure in 2026 to be

between $2 billion and $5 billion, compared with its initial

plans to spend about $5 billion per year through 2026 to build

out its manufacturing capacity.

(Reporting by Arsheeya Bajwa in Bengaluru)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Alliance Resource Partners' Q3 Earnings, Revenue Fall
Alliance Resource Partners' Q3 Earnings, Revenue Fall
Nov 3, 2024
07:39 AM EDT, 10/28/2024 (MT Newswires) -- Alliance Resource Partners ( ARLP ) reported Q3 earnings Monday of $0.66 per diluted limited partner unit, down from $1.18 a year earlier. Two analysts polled by Capital IQ expected normalized earnings of $0.82. Total revenue for the quarter ended Sept. 30 was $613.6 million, down from $636.5 million. Three analysts polled by...
Biogen Says Phase 2 Trial of Felzartamab Shows 'Substantial Reductions' in Proteinuria Levels, Kidney Function Stabilization
Biogen Says Phase 2 Trial of Felzartamab Shows 'Substantial Reductions' in Proteinuria Levels, Kidney Function Stabilization
Nov 3, 2024
07:35 AM EDT, 10/28/2024 (MT Newswires) -- Biogen (BIIB) said late Saturday that a phase 2 clinical trial assessing felzartamab demonstrated substantial reductions in proteinuria levels, stabilization of kidney function, and sustained treatment impact over 18 months following the investigational drug's last dose. The trial enrolled 54 participants to evaluate felzartamab's safety and efficacy in patients with Immunoglobulin A nephropathy...
BRIEF-Uranium Royalty Acquires Existing Royalty On Cameco's Advanced Stage Millennium And Cree Extension Uranium Projects
BRIEF-Uranium Royalty Acquires Existing Royalty On Cameco's Advanced Stage Millennium And Cree Extension Uranium Projects
Nov 3, 2024
Oct 28 (Reuters) - Uranium Royalty Corp ( UROY ): * URANIUM ROYALTY ACQUIRES EXISTING ROYALTY ON CAMECO'S ADVANCED STAGE MILLENNIUM AND CREE EXTENSION URANIUM PROJECTS * URANIUM ROYALTY CORP ( UROY )- PROPOSED DEAL FOR FOR TOTAL CASH CONSIDERATION OF $6 MILLION Source text: Further company coverage: ...
Commerzbank Asks If Russia's Central Bank Is Overdoing It in Monetary Tightening
Commerzbank Asks If Russia's Central Bank Is Overdoing It in Monetary Tightening
Nov 3, 2024
07:38 AM EDT, 10/28/2024 (MT Newswires) -- Russia's central bank (CBR) has always been a credible and prudent central bank in the emerging market world, said Commerzbank. The bank admired its past decisions when the CBR hiked rates right after government figures demanded rate cuts from time to time. Impeccable credentials notwithstanding, Commerzbank now asked whether or not CBR might...
Copyright 2023-2026 - www.financetom.com All Rights Reserved